Syndax Pharmaceuticals's total assets for Q3 2025 were $551.79M, a decrease of -7.44% from the previous quarter. SNDX total liabilities were $436.36M for the fiscal quarter, a -0.54% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.